Metacrine (NASDAQ:MTCR) Shares Up 9.5%
Metacrine (NASDAQ:MTCR) Shares Up 9.5%
In other news, major shareholder Braden Michael Leonard acquired 123,954 shares of Metacrine stock in a transaction dated Monday, November 7th. The stock was purchased at an average cost of $0.42 per share, with a total value of $52,060.68. Following the completion of the purchase, the insider now directly owns 5,848,649 shares in the company, valued at approximately $2,456,432.58. The transaction was disclosed in a document filed with the SEC, which is available through Metacrine, Inc. (NASDAQ:MTCR – Get Rating)'s share price shot up 9.5% on Wednesday . The company traded as high as $0.50 and last traded at $0.48. 1,115,206 shares were traded during trading, an increase of 455% from the average session volume of 200,925 shares. The stock had previously closed at $0.44.
梅特克林公司 (NASDAQ: MTCR — 獲取評分) 的股價上漲 9.5% 在星期三。該公司的交易價格高達 0.50 美元，最後交易價格為 0.48 美元。在交易過程中交易了 1,115,206 股，較 200,925 股的平均交易量增加了 455%。該股票之前已收盤 0.44 美元。
Wall Street Analysts Forecast Growth
華爾街分析師預測增長
Separately, HC Wainwright reaffirmed a "neutral" rating on shares of Metacrine in a report on Wednesday, November 16th.
另外，HC 溫賴特在 11 月 16 日（星期三）的一份報告中重申了對安特克林股票的「中性」評級。
Metacrine Trading Up 9.5 %
甲基林交易增長 9.5％
The firm has a market capitalization of $20.60 million, a PE ratio of -0.47 and a beta of -0.92. The company has a quick ratio of 12.15, a current ratio of 12.15 and a debt-to-equity ratio of 0.34. The stock's fifty day simple moving average is $0.42 and its 200 day simple moving average is $0.45.
該公司的市值為 20.60 萬美元，PE 比率為 -0.47，貝塔值為 -0.92。該公司的快速比率為 12.15，流動比率為 12.15，債務與權益比率為 0.34。該股的五十天簡單移動平均線為 0.42 美元，其 200 日簡單移動平均線為 0.45 美元。
Insider Buying and Selling at Metacrine
在 Metacrine 進行內幕購買和銷售
In other news, major shareholder Braden Michael Leonard acquired 123,954 shares of Metacrine stock in a transaction dated Monday, November 7th. The stock was purchased at an average cost of $0.42 per share, with a total value of $52,060.68. Following the completion of the purchase, the insider now directly owns 5,848,649 shares in the company, valued at approximately $2,456,432.58. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last ninety days, insiders acquired 430,275 shares of company stock valued at $174,191. Insiders own 11.40% of the company's stock.
在其他消息中，主要股東布拉登·邁克爾·倫納德在 11 月 7 日（星期一）的交易中收購了 123,954 股梅特克林股票。該股票以每股 0.42 美元的平均成本購入，總價值為 52,060.68 美元。購買完成後，內幕人士現在直接擁有該公司 5,848,649 股股份，價值約為 2,456,432.58 美元。該交易在向 SEC 提交的文件中披露，該文件可通過以下方式獲得 證券交易所網站。在過去九十天內，內部人士收購了價值 174,191 美元的 430,275 股公司股份。業內人士擁有公司股票的 11.40%。
Institutional Trading of Metacrine
米特琳的機構交易
Hedge funds and other institutional investors have recently modified their holdings of the company. State Street Corp increased its stake in shares of Metacrine by 482.8% in the second quarter. State Street Corp now owns 72,186 shares of the company's stock worth $36,000 after purchasing an additional 59,800 shares in the last quarter. Citadel Advisors LLC grew its stake in Metacrine by 112.5% during the third quarter. Citadel Advisors LLC now owns 136,606 shares of the company's stock valued at $66,000 after acquiring an additional 72,306 shares in the last quarter. Jane Street Group LLC purchased a new position in Metacrine during the third quarter valued at $84,000. Bank of New York Mellon Corp purchased a new position in Metacrine during the first quarter valued at $126,000. Finally, Bank of America Corp DE grew its stake in Metacrine by 10.5% during the first quarter. Bank of America Corp DE now owns 263,340 shares of the company's stock valued at $161,000 after acquiring an additional 24,964 shares in the last quarter. 34.28% of the stock is owned by hedge funds and other institutional investors.
對沖基金和其他機構投資者最近修改了他們對該公司的持有量。國街公司在第二季度將其在梅特克林股份的股份增加了 482.8％。州街公司現在擁有該公司股票的 72,186 股，價值 36,000 美元，在上一季度額外購買 59,800 股股票。城堡顧問有限責任公司在第三季度將其在梅塔克林的股份增長了 112.5％。城堡顧問有限責任公司現在擁有該公司股票的 136,606 股，價值為 66,000 美元，在上個季度獲得了額外的 72,306 股之後。簡街集團有限責任公司在第三季度購買了 Metacrine 的新職位，價值為 84,000 美元。紐約梅隆銀行在第一季度購買了一個新的位置，價值為 126,000 美元。最後，美國銀行公司 DE 在第一季度將其在梅塔克林的股份增長了 10.5％。美國銀行股份有限公司在上一季度額外收購了 24,964 股後，現在擁有該公司股票 263,340 股，價值 161,000 美元。34.28％ 的股票由對沖基金和其他機構投資者擁有。
About Metacrine
關於梅塔克林
(Get Rating)
(取得評分)
Metacrine, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc was incorporated in 2014 and is headquartered in San Diego, California.
Metacrine, Inc 是一家臨床階段生物製藥公司，致力於發現和開發針對胃腸疾病患者的療法。它正在開發 MET642，該試驗已完成治療潰瘍性結腸炎的 I 期臨床試驗。梅塔克林公司成立於 2014 年，總部位於加利福尼亞州聖地牙哥。
Read More
閱讀更多
- Get a free copy of the StockNews.com research report on Metacrine (MTCR)
- Two Dividend Kings: Johnson & Johnson or Abbott Laboratories?
- Is The Bottom In For Cyber-Security Stocks?
- Union Pacific, Norfolk Southern Pull into Buying Zone
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- 獲取有關二甲基林（MTCR）的研究報告的免費副本
- 兩個紅利國王：約翰遜或雅培實驗室？
- 網絡安全股票的底部是什麼？
- 聯合太平洋，諾福克南部進入購買區
- 普利安特治療學缺口 34％ 更高：更多的上升空間來？
- 2023 年初裁員將如何影響這 5 種生物技術股票？
Receive News & Ratings for Metacrine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metacrine and related companies with MarketBeat.com's FREE daily email newsletter.
接收梅塔克林日報的新聞和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收 Metacrine 及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。
